ACBD3 Mouse anti-Human, Clone: OTI3E7, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA525988
DescriptionGOLPH1, also known as GCP60, was initially identified as a Golgi protein that can interact with the integral membrane protein giantin and is thought to be involved in the maintece of the Golgi structure. GOLPH1 has also been shown to interact with other Golgi proteins such as Golgin-160, a Golgi protein that can be cleaved by caspases-2, -3, and -7, leading to the nuclear localization of Golgin-160. GOLPH1 interaction with the Golgin-160 fragments is stronger than that with the intact Golgin-160, with its interaction regulated by the oxidation state of Cys-463 within GOLPH1, suggesting that the nuclear localization of the caspase-cleaved Golgin-160 fragments is a highly coordinated event. GOLPH1 has also been found to interact with Numb, a cytosolic signaling protein that mediates asymetric cell division of neural progenitor cells to a daughter progenitor cell and a neuron, suggesting that Golgi fragmentation and reconstitution during the cell cycle differentially regulate Numb signaling through changes in GOLPH1 subcellular distribution and may couple cell fate with cell cycle progression.
|PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3|
|GCP60, GOCAP1, GOLPH1, PAP7; Golgi resident protein GCP60; PBR- and PKA-associated protein 7; PKA (RIalpha)-associated protein; acyl-Coenzyme A binding domain containing 3; golgi complex associated protein 1, 60kDa; golgi phosphoprotein 1; peripheral benzodiazepine receptor-associated protein PAP7|
|-20° C, Avoid Freeze/Thaw Cycles|
|Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot|
|Full length human recombit protein of ACBD3 produced in HEK293T cell|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok